IAM
CRL icon

Iridian Asset Management’s Charles River Laboratories CRL Stock Holding History

Iridian Asset Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-9,845
Closed -$1.7M – 42
2026
Q1 		$1.7M Sell
9,845
-16,723
-63% -$3.1M 0.69% 32
2025
Q4 		$5.3M Sell
26,568
-2,058
-7% -$373K 1.95% 18
2025
Q3 		$4.48M Sell
28,626
-18,940
-40% -$3.01M 1.76% 20
2025
Q2 		$7.22M Sell
47,566
-12,853
-21% -$1.71M 2.5% 13
2025
Q1 		$9.09M Buy
60,419
+9,454
+19% +$1.59M 2.85% 12
2024
Q4 		$9.41M Sell
50,965
-4,078
-7% -$786K 2.5% 14
2024
Q3 		$10.8M Buy
55,043
+8,876
+19% +$1.84M 2.32% 17
2024
Q2 		$9.54M Buy
46,167
+21,763
+89% +$4.93M 2.15% 17
2024
Q1 		$6.61M Sell
24,404
-6,738
-22% -$1.61M 1.3% 19
2023
Q4 		$7.36M Buy
31,142
+1,803
+6% +$355K 1.34% 15
2023
Q3 		$5.75M Sell
29,339
-38,039
-56% -$7.81M 1.16% 22
2023
Q2 		$14.2M Buy
67,378
+1,309
+2% +$260K 1.32% 22
2023
Q1 		$13.3M Sell
66,069
-12,607
-16% -$2.86M 1.09% 24
2022
Q4 		$17.1M Sell
78,676
-9,288
-11% -$2.03M 1.65% 21
2022
Q3 		$17.3M Sell
87,964
-4,771
-5% -$1.03M 1.72% 24
2022
Q2 		$19.8M Buy
92,735
+18,245
+24% +$4.46M 1.62% 25
2022
Q1 		$21.2M Buy
74,490
+15,974
+27% +$4.93M 1.47% 28
2021
Q4 		$22M Sell
58,516
-52,277
-47% -$20.3M 1.35% 34
2021
Q3 		$45.7M Sell
110,793
-95,394
-46% -$39.6M 1.4% 33
2021
Q2 		$76.3M Sell
206,187
-34,754
-14% -$11.6M 1.33% 39
2021
Q1 		$69.8M Sell
240,941
-39,566
-14% -$11M 1.19% 37
2020
Q4 		$70.1M Sell
280,507
-42,648
-13% -$10.2M 1.28% 35
2020
Q3 		$73.2M Sell
323,155
-113,625
-26% -$23.6M 1.6% 32
2020
Q2 		$76.2M Sell
436,780
-40,377
-8% -$6.44M 1.68% 30
2020
Q1 		$60.2M Buy
477,157
+266,270
+126% +$39.9M 1.46% 30
2019
Q4 		$32.2M Buy
+210,887
New +$29.2M 0.53% 46

Other funds holding CRL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75.4B AUM 14.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return

Iridian Asset Management's CRL Position: Q2 2026 in Review

Iridian Asset Management sold out of Charles River Laboratories (CRL) in Q2 2026, closing a stake of 9,845 shares — an estimated $1.7M sold.

Iridian Asset Management first reported a position in CRL in Q4 2019 and held it in 26 quarters. The position peaked at $76.3M in Q2 2021. 569 funds tracked by Wall St. Rank hold CRL as of Q2 2026.

  • Iridian Asset Management reported no remaining Charles River Laboratories position as of Q2 2026 after selling out during the quarter.
  • Iridian Asset Management sold 9,845 Charles River Laboratories shares in Q2 2026, an estimated $1.7M.
  • Iridian Asset Management first reported a position in Charles River Laboratories in Q4 2019 and held it in 26 quarters.
  • Iridian Asset Management's Charles River Laboratories position peaked at $76.3M in Q2 2021.
  • 569 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.

Based on Iridian Asset Management's 13F filing for Q2 2026, filed 29 Jul 2026.